Brought to you by 
Ono gets rights to Array's binimetinib and encorafenib
31 May 2017
Executive Summary
Array BioPharma Inc. granted Ono Pharmaceutical Co. Ltd. exclusive rights to develop and sell in Japan and South Korea its cancer candidates binimetinib and encorafenib, which are both in Phase III trials for BRAF-mutant melanoma and BRAF-mutant colorectal cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ono gets rights to Array's binimetinib and encorafenib
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice